Merus (NASDAQ:MRUS) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS) in a research note issued to investors on Friday, Benzinga reports. The firm currently has a $65.00 target price on the biotechnology company’s stock.

A number of other research analysts have also recently weighed in on MRUS. Needham & Company LLC reiterated a buy rating and issued a $66.00 target price on shares of Merus in a report on Monday, May 13th. Truist Financial assumed coverage on shares of Merus in a research report on Thursday, March 28th. They set a buy rating and a $69.00 target price for the company. BMO Capital Markets lifted their price target on shares of Merus from $49.00 to $58.00 and gave the company an outperform rating in a research report on Thursday, February 29th. Stifel Nicolaus increased their price objective on shares of Merus from $40.00 to $65.00 and gave the stock a buy rating in a research report on Thursday, February 29th. Finally, StockNews.com cut shares of Merus from a hold rating to a sell rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $56.80.

Merus Stock Up 36.1 %

MRUS traded up $15.92 during midday trading on Friday, hitting $59.99. The company’s stock had a trading volume of 6,908,179 shares, compared to its average volume of 750,143. Merus has a 52-week low of $19.81 and a 52-week high of $61.61. The firm has a 50-day moving average price of $44.30 and a two-hundred day moving average price of $37.04.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.24. The firm had revenue of $7.89 million during the quarter, compared to analyst estimates of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. On average, research analysts expect that Merus will post -3.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of MRUS. Quadrant Capital Group LLC raised its position in shares of Merus by 37.7% during the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 343 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Merus by 64.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock worth $58,000 after buying an additional 828 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Merus in the 1st quarter valued at about $72,000. SG Americas Securities LLC bought a new stake in shares of Merus during the 1st quarter valued at about $108,000. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Merus by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 1,459 shares during the last quarter. Institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.